Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Figure skater Michelle Hong used to hide her skin as much as possible due to her condition—but with effective treatment and ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Doctors report a steady increase in eczema cases among infants across Indian cities. Experts warn that genetics and ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Nektar Therapeutics (NKTR) saw its stock surge 86% Tuesday morning after reporting strong midstage trial results for its ...